Imatinib-Induced Interstitial Lung Disease:A Case Report by Al-Mashhadi, Ahmed Ludvigsen et al.
 
  
 
Aalborg Universitet
Imatinib-Induced Interstitial Lung Disease
A Case Report
Al-Mashhadi, Ahmed Ludvigsen; Stentoft, J.; Roug, Anne Stidsholt
Published in:
Austin Hematology
Creative Commons License
Unspecified
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Al-Mashhadi, A. L., Stentoft, J., & Roug, A. S. (2018). Imatinib-Induced Interstitial Lung Disease: A Case Report.
Austin Hematology, 3(1), 1-3. [1019].
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 24, 2020
Citation: Al-Mashhadi AL, Stentoft J and Roug AS. Imatinib-Induced Interstitial Lung Disease: A Case Report. 
Austin Hematol. 2018; 3(1): 1019.
Austin Hematol - Volume 3 Issue 1 - 2018
Submit your Manuscript | www.austinpublishinggroup.com 
Al-Mashhadi et al. © All rights are reserved
Austin Hematology
Open Access
Abstract
For more than a decade, Tyrosine Kinase Inhibitors (TKI) has been standard 
of care in the treatment of BCR-ABL positive Chronic Myeloid Leukemia (CML). 
The treatment has revolutionized the approach to CML and a vast majority of 
patients can now have unaltered lifespan with lifelong treatment. Generally the 
treatment is well tolerated with high-grade toxicities being rare. In this case 
report, a 69-year-old male patient with newly diagnosed chronic phase CML 
had a rapid hematological and compelling molecular response to imatinib 
mesylate (imatinib), but developed severe progressive Interstitial Lung Disease 
(ILD) within the first 3 months of treatment. Drug discontinuation and combined 
immunosuppressive therapy, with corticosteroids and azathioprine, alleviated 
the pulmonary symptoms, chest radiographs improved significantly, and the 
patient achieved nearly complete pulmonary recovery. This case report serves to 
raise awareness of ILD as a rare but very serious complication of TKI treatment 
in CML, where early diagnosis and intervention is of utmost importance since 
the condition is potentially life threatening, if unrecognized.
Keywords: Chronic myeloid leukemia; Tyrosine kinase inhibitor; Interstitial 
lung disease
hypertension. Lung function test shortly after corticosteroid treatment 
showed typical restrictive lung disease pattern consistent with 
interstitial disease (FEV1/FVC 100%, FVC 77% of expected, DLCO/
VA 58% of expected). Transbronchial lung biopsy or bronchoalveolar 
lavage was not performed.
Imatinib-induced ILD (grade 2) was suspected, the culprit TKI was 
discontinued, and a 14-day course of prednisolone (75mg OD) was 
started, which was effective but inadequate. Hence, prednisolone was 
resumed (50mg OD) alongside azathioprine (150mg OD, 11 weeks) 
by which a slow but steady clinical and radiological improvement 
was attained (Figure 3 a-f). Due to rising levels of the BCR-ABL 
transcript, nilotinib was introduced (300mg BID) with good response 
(Figure 1). Five months after discontinuation of imatinib, the patient 
was still treated with prednisolone (12.5 mg/day) and nilotinib. The 
pulmonary symptoms had nearly recovered and chest radiographs 
almost normalized (Figure 3f).
Discussion
The approval of imatinib in 2001 as the first molecularly targeted 
TKI not only led to breakthrough treatment of BCR-ABL positive 
CML [4], but also heralded a new era in the treatment of neoplastic 
disorders in general. Five TKIs are currently available for clinical use 
in CML. Overall, these drugs are well tolerated and highly effective, 
but treatment related complications do occur. The most prominent 
side effects of imatinib treatment are nausea, diarrhea, edema, muscle 
cramps, rash, fatigue, and bone marrow suppression. Among the most 
serious adverse effects of second generation TKIs, cardiovascular 
disease dominates [5]. Although rare, more than 50% of all approved 
TKIs have been reported to induce ILD including imatinib, dasatinib 
and nilotinib. It presents with varying severity and the reported 
mortality rates are in the range of 20-50% when untreated [6-8].
Case Presentation
A 69-year-old male presented with significant leukocytosis and a 
4-months history of weight loss and fatigue. There was no prior history 
of smoking, cardiac or pulmonary disease, nor any other significant 
comorbidity. Also, there was no history of toxic exposure in the 
workplace. At diagnosis the total leukocyte count was 146x109/L, 
hemoglobin 11.8g/dl, and platelets 1159x109/L. The spleen was not 
enlarged. Bone marrow examination showed chronic phase CML 
with 5% blasts and 12% basophils and cytogenetic analysis revealed 
46, XY, t(9;22) (q34;q11) [25/25]. The Sokal [1] and ELTS [2] scores 
were 2.02 (high risk) and 1.84 (intermediate risk), respectively.
The patient was started on standard dose imatinib (400mg OD). 
Hematologic remission was achieved within 4 weeks, and after 12 
weeks a compelling molecular response, as measured by qPCR, was 
accomplished (MR5 with BCR-ABL below 0.001% IS in peripheral 
blood) (Figure 1) [3]. Grade 1 periorbital edema was the only side 
effect experienced during the initial 9 weeks of treatment, after 
which there was an insidious and progressive dyspnea and non-
purulent secretory cough, but no fever. Chest examination revealed 
end-expiratory crackles, and chest X-ray verified bilateral perihilar 
infiltrates. C-reactive protein was slightly elevated to 52 g/L (Figure 
2b), but hypoxemia was not observed. Antibiotics were ineffective. 
Repeated chest radiograph showed progression of the perihilar 
infiltrates and regular Computed Tomography (CT) scan verified 
marked pathology with bilateral infiltration, ground-glass opacity 
and generalized bronchiectasis (Figure 3b-d). There were no signs 
of malignancy or lymph-node pathology in the thorax, abdomen 
or pelvic regions. The dyspnea had now become debilitating. High 
Resolution CT scan verified the standard CT findings resembling ILD 
(Figure 3e). Echocardiography was normal with no sign of pulmonary 
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ILD can occur secondary to a broad range of systemic diseases, 
after many different exposures including as drug toxicity. Most 
frequently it presents with dyspnea, cough, fever, and hypoxemia due 
to chronic inflammation and/or skin damage resulting in progressive 
fibrosis. The diagnosis is supported by the case history, relevant 
exposure, and radiological findings, but lung biopsy may be necessary 
for accurate diagnosis. Extensive diagnostic work-up may also be 
needed with regard to primary disease.
The pathophysiology of TKI-induced ILD remains unclear, but 
is believed to be multifactorial. Generally pneumotoxic agents cause 
alveolitis and edema, which initiate various mechanisms to repair the 
lung tissue [9]. Acute injury may, on occasion, result in detrimental 
chronic inflammation and, eventually, fibrosis that compromises gas 
exchange. Some compounds and their metabolites have been shown 
to interact with HLA and act as potential antigens or haptens causing 
a drug-specific immuno-allergic response [10]. Recent data indicate 
TKIs may behave in a similar manner [11,12]. Speculatively, the 
cytolysis resulting from the compelling decrease in tumor burden in 
the case presented, could have resulted in a severe cytokine release, 
a so-called “cytokine storm”, which may have contributed to an 
inflammatory response. The intensity and time course of the protective 
effect of the combination of corticosteroids and azathioprine, further 
add credence to the perception that immune mechanisms are indeed 
involved in TKI-induced ILD.
The susceptibility and likelihood of developing TKI-induced 
ILD remain obscure. Certain risk factors have been identified with 
both extremes of age, radiation therapy, underlying lung disease, and 
concomitant administration of pulmonary toxic agents being the 
most pronounced. In addition, ethnicity seems to play an important 
role. Specifically, the Japanese population has a significantly increased 
incidence of ILD as compared to other nationalities, which most 
likely may reflect a specific genetic susceptibility [7].
There is no general consensus in treating drug induced ILD. The 
use of corticosteroid-sparing systemic immunosuppression, in this 
case azathioprine, which particularly impedes B- and T lymphocyte 
proliferation [13], has only been sparsely reported in the treatment of 
TKI-induced ILD, but may be a viable and effective option as we have 
demonstrated. The expected tumor flare-up after discontinuation 
of imatinib necessitated re-challenge of TKI treatment with good 
response (Figure 1). Reportedly, for some patients, re-administration 
or continuation of the culprit TKI in a reduced dose under 
corticosteroid cover may be successful [6]. In CML however there 
are now a number of effective TKIs available and reintroduction 
of a culprit TKI should be restricted to cases where no alternatives 
remain, e.g. lack of response, unwanted drug interactions, or other 
potent side effects.
With this case report we hope to place emphasis on the importance 
of vigilant monitoring of early and late toxicity, concurrent 
morbidity, and drug interactions along with efficacy of treatment 
in CML patients. The diagnosis of TKI-induced ILD remains a 
diagnosis of exclusion and may be hampered by non-specific findings 
and idiosyncratic toxicities. Early treatment may reduce the high 
Figure 1: Progression of leukocyte count and qPCR levels of BCR-ABL1 
transcript in peripheral blood.
Figure 2: Diagnostic imaging during treatment course illustrating progressive 
interstitial disease.
(a) Pretreatment X-ray; X-ray after introduction of Imatinib for; (b) 9 weeks; 
(c) 13 weeks; (d and e) 16 weeks. (e) HRCT showing ground-glass opacity, 
bronchiectasis and fibrosis.
Figure 3: X-ray controls after discontinuation of Imatinib and introduction of 
immunosuppressive therapy after (a) 1 weeks; (b) 3 weeks; (c) 5 weeks; (d) 
8 weeks; (e) 14 weeks; (f) 23 weeks.
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mortality rates that have been reported. Therefore patients presenting 
with unexplained fever, cough, and dyspnea, even several months 
after starting TKI treatment, should be investigated and treated 
for ILD. Besides immediate discontinuation of the culprit TKI and 
initiation of high-dose corticosteroids, systemic corticosteroid-
sparing immunosuppression should be considered.
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